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HLA matching for renal transplantation in normal and sensitized
patients. D.E. Speiser, T. W. Frick, C'. Goumaz, G. Opelz, and M. Jeannet,
Laboratoire National de Reference pour l'Histocompatibilité, Swisstrans-
plant, and the Collaborative Transplant Study, Hôpital Cantonal Universi-
taire, Genève, Switzerland. HLA mismatches between donor and patient
significantly reduce kidney allograft survival despite the use of multiple
immunosuppressive drugs. The main risk factor for rejection and graft
failure is pretransplant alloimmunization of the patient by blood transfu-
sions, pregnancies or previous allografts. Special kidney exchange pro-
grams have been established for priority allocation of HLA matched grafts
to immunized (high risk) patients. Fortunately, these programs increased
the chance to find a suitable donor and significantly improved graft
survival in immunized patients. In contrast, no HLA matching exchange
program exists in our countly for the non-immunized (low risk) patients.
We have retrospectively analyzed graft survival in 1,656 consecutive
cadaveric transplants in Switzerland in the years 1981 through 1992 in
patients treated with cyclosporine A. The overall probability of 5 year graft
survival was 71%. We compared patients with better versus less well HLA
matched grafts. The better matched group A was compatible for at least
1A, 1B, and 1DR (N = 667); the less well matched group B was >1
antigen mismatched at the A, B, and/or DR locus (N = 978). The
probability of 5 year graft survival was 73% vs. 69% (NS). According to
our kidney allocation strategy group A contained much more high risk
patients than group B (high risk was defined as >50% panel reactive
antibodies or retranspiantation). Therefore, we repeated the analysis after
exclusion of all the high risk patients from both groups. Now the 5 year
graft survival of the better (N 419) versus the less well (N 809)
matched transplants was 78% versus 69% (P < 0.005; log-rank test). These
data show that good HLA matching improves graft outcome also in
non-immunized patients.
Non-related living kidney donation: First experience in Switzerland. I.
Binet, A. Bock; T Gasser, J. Landmann, A. Kiss, and G. Thiel, Departeinent
Medizin und Chirurgie, Kantonsspital Basel, Basel, Switzerland. Due to a
continuous shortage of cadaveric organs, the program for living related
donation was expanded in Basel to emotionally related donation. On May
16th 1991, the kidney of a woman was transplanted into her uremic
husband for the first time in Switzerland. The high motivation of the
donor, the lack of somatic contraindications and the official acceptance of
emotionally related donation by an international conference on ethics in
transplantation (Munich 1990) were arguments to convince our team to
start a program for non-related living donor kidney transplantation
(nrldkt). Fourteen nrldkt were performed until September 1994. All
donors were carefully evaluated before transplantation by one of two
independent psychologists (A. Kiss or W. Langewitz) outside the trans-
plant team. The median age of recipients was 50.0 years (range 28—69
years) and of donors was 49.5 years (range 36—64 years). There were 6
donations from wives, 2 from heterosexual female partners, 5 donations
from husbands, and 1 from a step-father. Nrldkt was performed as first
treatment of end-stage uremia in 6 patients, thus avoiding dialysis. None
of the recipients had cytotoxic antibodies prior to nrldkt. The mean
number of HLA-A/B/DR mismatches (MM) was 4.2 (3 MM in 3 patients;
4 MM in 6 patients; 5 MM in 3 patients; and 6 MM in 2 patients).
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Patient/graft survival: All recipients and donors survived. All but 1
transplanted kidney are still functioning; the actuarial one year survival
reached 93%. The one failing graft suffered from a severe vascular
rejection and was removed at day 22. Renal function: Median of the last
plasma creatinine was 122 jtmol/liter (range 74—172). Social rehabilita-
tion: 11/13 patients with grafts now work full time and 2/13 are retired but
are in excellent condition. Median delay between transplantation and
return to full occupational life was 3 months (range 2—7 months). No
relevant donor complications occurred; all donors are back to their
previous life. None has regretted donation, not even the one whose kidney
was rejected. Conclusions: (1) This first experience with nrldkt in Swit-
zerland is encouraging concerning graft survival, rapid socio-economic
rehabilitation and possible avoidance of dialysis. (2) Donation was never
regretted, not even in the case of graft failure. (3) In carefully selected
patients nrldkt is an acceptable therapy for end-stage renal failure.
Cyclosporine A therapy functionally impairs prorenin-to-renin conver-
sion in the afferent arteriole. HA. Bock, K Weber, M. Zeiler, M.J.
Mihatsch, and G. Thie4 Abteilung Nephrologie und Departement Pathologie,
Kantonsspital Basel, Basel, Switzerland. Plasma prorenin has been reported
to be increased in heart transplant patients with cyclosporine A (CsA)
associated arteriolopathy (CAA) due to impaired prorenin-to-renin con-
version in the afferent arteriole. To determine whether this increase is
related to CsA therapy as such, or to CAA, we prospectively measured
plasma renin and prorenin in CsA treated renal (RT) and bone marrow
transplant (BMT) recipients; living related kidney donors (LRKD) and
BMT patients without CsA served as controls. Prorenin was measured as
trypsin-activatable renin activity, and the ratio of prorenin to the log of
renin (ProLogR, normal range: 63—286) was used to correct for the
sodium dependence of prorenin. Patients on ACE inhibitors were ex-
cluded. In CsA treated RT patients, ProLogR increased significantly over
baseline within 48 hours of transplantation. CsA treated BMT patients
had significantly lower GFR (54% of control) and higher ProLogR (2.2 X
control) than before transplantation, but both parameters nearly normal-
ized after discontinuation of CsA (GFR: 89%, ProLogR: 1.3 x control).
Pre-
transplant/
Nx 2 weeks
LRKD no CsA 174 8 [46] 189 10 [491
RT CsA 209 21 [21] 455 17 [98]
BMT no CsA
CsA
177 11 [351 —
—
6 months 1 year
LRKD no CsA — 190 9 [25]
RT GsA 472 35 [25] 484 33 [22]
BMT no CsA
CsA
227 36 [4]
343 29 [18]ab
215 21 [9]
396 29 [1flab
Data are mean SEM [N] of ProLogR; "P < 0.05 vs. pre-Transpl, b vs.
no CsA
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Biopsied RT recipients had significantly higher ProLogR if the histology
included CAA (605 74 [fl) than if it did not (456 24 [981, P < 0.05),
but there was considerable overlap. In conclusion, CsA therapy causes an
increase of plasma prorenin within 48 hours, which is reversible upon
discontinuation. This time course suggests a functional, not structural,
basis for impaired prorenin-to-renin conversion which parallels CsA
induced vasoconstriction and occurs long before the development of CAA.
Study of this mechanism may help to elucidate the pathogenesis and
peculiar organ predilection of CAA.
Does rifampicine alter outcome of staphylococcal infections in CAPD
patients? G. Ashuntantang, P-Y. Martin, and H. Favre, Hôpital Cantonal
Universitaire, Genève, Switzerland. Staphylococcus aureus is the most
common cause of exit site infection, with catheter removal required in
about 25% of cases. Both Staphylococcus aureus and Staphylococcus
epidermidis are responsible for 70—80% of peritonitis. Rifampicine is
thought to be of benefit in CAPD staphylococcal infections due to its
ability to reach the biofilm of the tubing and also its capacity to penetrate
defective peritoneal macrophages which harbor viable organisms, thus
destroying them. Several antibiotic regimens are being used against these
infections with varying efficacy reported. A regimen comprising vancomy-
cm i.v. or i.p. or teicoplanin i.v. for 14 to 21 days with addition of
rifampicine (600 mg per os) on the 4th day if symptoms persist was
instituted in our center in July 1986. We carried out a 7 year retrospective
study to evaluate the impact of this regimen on the outcome of these
infections. Of the 85 episodes of staphylococcal infections seen during this
period there were 50 exit site and 35 peritonitis episodes. Vancomycin or
teicoplanin alone was used in 57 episodes while rifampicine was added to
vancomycin or teicoplanin in 28 episodes. Eight of the 57 episodes without
rifampicine required catheter removal to eradicate the infection, while
one of the 28 episodes with rifampicine also required catheter removal.
This difference was not statistically significant (P > 0.1). There were six
episodes with resistant strains to rifampicin and none to vancomycin. We
conclude that rifampicin may improve catheter survival in CAPD staphy-
lococcal peritonitis and exit site infections but should remain a second line
drug to avoid emergence of resistant strains. A controlled prospective
study is required to confirm this finding.
Thrice versus once weekly i.v. administration of erythropoietin in
chronic hemodialysis (HD) patients. D. Kiss, 1. Rosier, and J. Haifmann,
Nephrology, Department of Internal Medicine, Kantonsspitai, Liestal, Swit-
zerland. In order to find Out the effect of the change of the dose interval
of intravenous recombinant human erythropoietin (rHuEPO) from 3 x/
week to 1 X/week, administration of rHuEPO in chronic HD patients, 20
patients were investigated over 24 months. Only chronic HD patients
treated with rHuEPO for more than 6 months were included in the study.
rHuEPO was administered 3X/week intravenously in all patients. To
maintain hemoglobin (Hb) concentration between 10.5—11.0 g/dl, the dose
was adjusted every month. The iron status was controlled every 2 months
and patients received iron substitution intravenously for 2 months when
ferritin was below 200 nglml. Under this 3X/week regimen patients were
treated for 12 months and then rHuEPO therapy was changed to 1 ></week
for 12 months.
Before 3 X/week 1 >< /week
rHuEPO Begin-study (12 months) (12 months)
Hb g/dl 7.8 0.8 10.7 0.6 10.8 0.7 10.8 0.8
rHuEPO, 0 80 25 92 32 80 37
U/week/kg
Ferritin, ng/ml 124 235 346 216 385 287 328 256
In the maintenance phase of rHuEPO therapy in chronic HD patients the
1 X/week i.v. administration of rHuEPO does not lead to an increase of the
required dose. Therefore, when the goal hemoglobin has been reached
during the treatment of anemia in chronic HD patients, a ix/week i.v.
administration of rHuEPO seems to be sufficient.
Comparison of pulse intravenous (i.v.) versus oral (p.o.) calcitriol
treatment of secondary hyperparathyroidism (HPT) in chronic hemodi-
alysis (HD) patients. D. Kiss, M Kraenzlin, and I. ROsier, Nephrology,
Department of Internal Medicine, Kantonsspital, Liestal, and Endocrine
Practice, Basel, Switzerland. In order to find out the differences of the effect
of calcitriol i.v. versus p.o. on the biochemical bone parameters, a
prospective analysis over 4 months each was performed in 20 chronic HD
patients with secondary HPT (i-PTH > 200 pg/ml). The patients received
calcitriol i.v. 3X/week after hemodialysis in a dose of I g. The biochem-
ical bone parameters [s-calcium (Ca), s-phosphorus (P), alkaline phos-
phatase (AP)] and i-PTH activity were measured initially every week and
as soon as s-calcium was stable, every month. To keep Ca between
2.50—2.70 mmol/liter and P < 1.80 mmol/liter the dose of calcitriol and the
dose of the phosphate binder were adjusted initially every week and then
every month. The Ca concentration of the dialysate was changed to 1.5
mmol/liter. Independently of the route of administration, calcitriol ther-
apy led to a significant increase of Ca and P concentration in 13/20
patients and a significant continuous reduction of i-PTH activity. The
effect of PTH suppression was independent of the route of administration.
In 4 patients bone pain developed during calcitriol therapy.
Beginning
After
4 months
i.v.
After
4 months
p.o.
Ca, mmol/liter 2.44 0.18 2.60 0.16 2.57 0.21
P, mmol/liter 1.64 0.46 1.70 0.41 1.79 0.55
i-PTH, pg/mi 276 84 90 44 80 33
Calcitriol, gig/week 3.0 0 1.50 0.35 1.54 0.87
In chronic HD patients with secondary HPT, calcitriol therapy leads to a
significant suppression of PTH activity, independently of the route of
administration. Due to many hypercalcemic episodes, increase of P and
bone pain in some patients, starting with low doses of calcitriol is
recommended.
Scanning force microscopy gives new insights of the inner surface of
dialyzer membranes. D. Kiss, P. Reimann, and 1. RosIer, Nephrologie,
Medizinische Klinilç Kantonsspital, Liestal, and Institut für Physik der
UniversitOt, Basel, Switzerland. Scanning force microscopy (SFM) is a new
method which provides three-dimensional real space images and allows
local measurements of topography, chemical and electronic structure with
high spacial resolution. We investigated the inner surface of new, used and
reprocessed capillary hollow fiber polysuiphone membranes (F-60). We
compared the results of conventional electron microscopy (EM) and
scanning electron microscopy (SEM) with the results obtained by SFM. In
contrast to EM and SEM, SFM provides three-dimensional, real space
images of the inner surface of the membrane, with a good correlation of
the magnification. After regular use of the dialyzer, different deposits on
the inner surface can be demonstrated, which are mainly located in and
around the pores of the membrane. After careful reprocessing of the
dialyzer the deposits are no longer detectable and the inner surface of the
membrane has the same structure as before use. We conclude that
scanning force microscopy is a new and sensitive method which provides
three-dimensional real space images of the topography of the inner
surface of dialyzer membranes. This method is superior to the other
imaging techniques. This technique gives completely new insights into the
ultrastructure of dialyzer membranes and seems to be a promising method
for further investigations.
Long-term anticoagulation with coumarins for vascular prosthesis in
hemodialysis patients. E. Helfenstein and A. Colombi, Nierenstation,
Medizinische Klini/ç Kantonsspital, Luzern, Switzerland. In hemodialysis
patients with polytetrafluorethylene (PTFE) prosthesis for vascular access,
long-term anticoagulation was performed with coumarins. Fifty-two pros-
theses were implanted in 37 patients (39 Gore-Tex and 13 Impra grafts).
Straight implantation mode was performed in only 7 cases, while the other
grafts were implanted as a loop with proximal arterial and venous
anastomosis. Coumarins were administered to keep Quick value between
25 and 40% corresponding to INR 2.9—1.7. Secondary patency rate was
71.4 7.0% at 1 year, 66.2 8.0% at 2 years, 59.7 9.5% at 3 years, and
36.5 14% after 5 years. The corresponding rates of the Gore-Tex
Vascular Graft Registry were 76%, 67% and 51% at 1, 2, and 3 years. The
data for primary patency rate (that is, patency until first revision) was 53.7
8.2% for 1, 44.8 9.6% for 3, and 34.8 14% for 5 years. Compared
with the Gore-Tex Vascular Graft Registry our results are equal during
Abstracts 297
the first two years and superior after 3 years by 9% (P < 0.001). Impra
grafts had a higher patency rate after 30 months (71.4 28.6) compared
with Gore-Tex grafts (57.3 10); however, the number of grafts is too
small for statistical significance. Increased local edema formation and
bleeding accidents might be the complications of coumarin anticoagula-
tion. The interval between implantation and first puncture showed no
correlation to secondary patency. In conclusion, anticoagulation of PTFE
grafts with coumarins for hemodialysis offers better long-term patency
rates compared to grafts without this mode of anticoagulation. An
increased tendency to local edema and bleeding might be the price.
Pharmacokinetics of fleroxacin after multiple dosing in patients on
chronic hemodialysis. D.E. Uehlinger, F. Schaedeli, E. Weidekamm, and
F..!. Frey, Department of Medicine, Division of Nephrology, University of
Berne, Berne, Switzerland. The pharmacokinetic profile of fieroxacin was
studied in 8 noninfected patients on chronic hemodialysis (4 women, 4
men, mean age 63 years, range 48 to 73 years). One patient was excluded
from analysis for noncompliance with drug intake; 3.5 hours after dialysis
was started, plasma levels of fieroxacin decreased to 61 10% (STD). A
rebound of 14 10% was observed 30 minutes after stopping hemodial-
ysis. Dialysis clearances calculated from dialysate drug recovery exceeded
those calculated from plasma extraction rates for fleroxacin (126 29 vs.
64 12 mI/mm) and its two major metabolites, N-oxide fleroxacin (100
26 vs. 93 13 mI/mm) and N-desmethyl fieroxacin (103 31 vs. 63 16
mI/mm). Data were fitted to a 2 compartment model over the total
observation period of 8 days (200 mg fleroxacin p.o. on days 1 to 6,
hemodialysis treatment on day 1, 3 and 6) using nonlinear mixed effects
modeling (NONMEM). The random variability of plasma fleroxacin was
about 13% of its prediction. Estimated metabolic clearance was 25 mI/mm
[43% coefficient of variation (CV)j and the calculated steady state volume
of distribution was 84 liters (16% Cv). Conclusion: Adequate description
of fleroxacin disposition necessitates a two compartment model. Due to
the slow metabolic clearance and intermittent dialysis treatment, steady
state conditions are not reached after one week of oral fleroxacin therapy.
Effect of nicotinate and orotate on urate-anion exchange in human
brush-border membrane vesicles (BBMV). F. Roch-Ramel and B. Guisan,
Institut de Pharmacologie et Toxicologie, Lausanne, Switzerland. Recent
observations on human BBMV strongly suggest that the first step in urate
reabsorption involved exchange of luminal urate with intracellular mono-
valent organic anions. To understand the mechanisms underlying the
uricosuric and antiuricosuric responses in humans, we investigated the
effects of nicotinate, which induces urate retention in humans (antiurico-
suric), and of orotate which in contrast increases urinary urate excretion
(uricosuric) on [14C}-urate transport in BBMV isolated from human renal
cortex. Intra- and extravesicular basic media were 300 mat mannitol and 20
mM HEPES-Tris, pH 7.4. BBMV were preloaded with 1 mM nicotinate or
orotate, and [14C}-urate uptake measured in preloaded and unloaded
(control) BBMV. Both anions strongly transstimulated [14C}-urate up-
take. After 15 seconds, uptakes were, respectively, 19 4, 52 6, and 56
8, pmol/mg protein (N = 3) in control, nicotinate and orotate preloaded
BBMv, respectively, for an equilibrium uptake of 43 6 pmol/mg
protein, demonstrating concentrative uptake. However, in the presence of
an inwardly oriented sodium gradient (100 mat NaC1), nicotinate (1 mM),
but not orotate, cis-stimulated 14C}-urate uptake when added to the
extravesicular medium. Fifteen second uptake in the presence of nicotin-
ate was 55 10 pmol/mg protein, compared to 14 2 pmol/mg protein
in absence of nicotinate (N = 3). Transport of [14C]-orotate itself was not
stimulated by the sodium gradient. We conclude that nicotinate is
antiuricosuric in humans because it is taken up into proximal cells by
sodium cotransport, and then from cells nicotinate exchanges with urate,
stimulating urate reabsorption. Orotate is not reabsorbed by sodium
cotransport. From the lumen, orotate might exchange with intracellular
urate favoring urate excretion.
Influence of unilateral nephrectomy on the activity of the 11j3-hydroxy-
steroid dehydrogenase in the remaining kidney. ThA Beck G. Escher,
B.F. Frey, and F.J. Frey, Abteilung für Nephrologie, Departement Innere
Medizin, Inseispital, Bern, Switzerland. In the kidney, 11 3-hydroxysteroid
dehydrogenase (1113-OHSD) plays a crucial role for blood pressure
regulation and salt homeostasis by conferring specifity to the mineralo-
corticoid receptors for aldosterone in the presence of glucocorticoids. The
purpose of the present investigation was to establish whether the activity
of 11/3-OHSD is modulated in the remaining nephrons following unilat-
eral nephrectomy (UNX). Therefore, female Wistar rats were sacrificed
either 24 hours or 2 weeks after UNX. The activity of 11f3-OHSD was
assessed in the remaining kidney and compared with that in the nephrec-
tomized kidney. For the assessment of the activity of the 1113-OHSD the
rats were injected with prednisolone and the concentration ratio of this
1113-OH steroid to its il-keto metabolite prednisone was determined 60
minutes after injection using a HPLC method; 24 hours after UNX a
significant increase of the prednisolone/prednisone ratio (1.81 0.96 vs.
1.44 0.23, mean SD, N = 10,P = 0.011) was observed, indicating a
decreased activity of 11/3-OHSD. No change of the activity was observed
2 weeks after UNX. In conclusion, the transitory decrease of the activity
of the 1 1/3-OHSD may cause an increased mineralocorticoid activity with
an enhanced urinary excretion of potassium and retention of sodium and
by that contribute to the adaptation to a reduced number of nephrons.
Clinical manifestations and diagnosis of primary hyperoxaluria (PH)
in Switzerland: Results of a survey. N. Kopp and F. Leumann, Universitats-
Kinderklinilç, Zurich, Switzerland. Early diagnosis of PH is difficult, and
little is known about its occurrence. A survey was carried out among Swiss
nephrologists concerning all patients residing in Switzerland with PH
observed between 1980 and 1994. A total of 25 patients from 18 families
was recorded. Eighteen patients were alive in June 1994. Of these, 14 were
not in end-stage renal failure, suggesting a (minimal) prevalence of 2 per
million population. According to the age at first manifestation, patients
could be classified into 3 groups: A: <1 yr (N = 7); B: 2—14 (median 5.2)
years (N = 12); and C: 15—37 (median 24) years (N = 6). However, PH was
diagnosed considerably later except in infants, that is, at the age of 12
years (median) in B and 34.5 years in C, respectively. Six patients already
required dialysis at the time of diagnosis despite a long history of
urolithiasis. Six patients were diagnosed by family screening; altogether
there were 15 familial cases. Five of the 25 patients had nephrocalcinosis
without stone formation, and five were pyridoxin sensitive. At least 21 of
the 25 patients had type I PH. PH may be more common than anticipated.
Greater awareness of PH should allow earlier diagnosis and hence
improve prognosis.
Occurrence of transient diabetes insipidus after intracranial hemor-
rhage in a premature infant. MA. Panchard, I. Rappaz, J.P. Guignard, C.L.
Fawer, and A. Calame, Service de Pédiatrie, CHUV Lausanne, Switzerland.
Inappropriate secretion of ADH with consequent hemodilution and
antidiuresis is a well-known complication of cerebral distress and intra-
cranial hemorrhage. We describe a case where the intracranial hemor-
rhage was associated with transient hyposthenuric polyuria. A premature
female twin neonate (GA: 26 weeks; BV: 1030 g) presented with severe
idiopathic RDS. After intubation at 10 minutes of life, she was given 2
doses (5 mI/kg) of artificial surfactant (exosurf). On day 2, she was
administered indomethacin (0.1 mg/kg, q 12 hr) for the closure of a patent
ductus arteriosus. An intraventricular hemorrhage arising from the left
choroid plexus was detected by ultrasound on the first day of life. Because
of a post-hemorrhagic ventricular dilation, repeated lumbar punctures
were performed from day 8 to 15. On day 9, transient thermal imbalance
was observed. Urine flow rate increased progressively, while the urine
specific gravity decreased. On day 14, urine output reached a maximal
value of 11 ml/kg per hour with a urine specific gravity of 1.001, a urine
osmolality of 100 mOsm/kg H2O, and a plasma osmolality of 304 mOsm/kg
H20. Plasma creatinine was 65 jsmol/liter. Hypotonic fluid was adminis-
tered in order to compensate for the hypotonic urinary losses, without
giving vasopressin. Urine output eventually decreased to reach 2.9 mI/kg
per hour on day 19, with a specific gravity of 1.007, a urine osmolality of
232 mOsm/kg H20, and a plasma osmolality of 280 mOsm/kg H20. The
overall results observed in this neonate suggest that the occurrence of
transient diabetes insipidus was a consequence of the cerebral insult
secondary to the intracranial hemorrhage. They indicate that: (1) intra-
cranial hemorrhage can induce both an inappropriate secretion of ADH
or a transient defect in ADH secretion; (2) the body fluid balance can be
maintained by thoroughly compensating the urinary losses, without the
need for exogenous vasopressin.
Spectrophotometric measurements of calcium oxalate crystal nucle-
ation and aggregation: Impact of various modifiers. U Meinhardt, R.
Giovanoli, Ph. Jaeger, and B. Hess, Medizinische Universitatspoliklinik Bern
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und Labor für Elektronenmikroskopie der Universitat Bern, Bern, Switzer-
land. Rates of nucleation and aggregation of calcium oxalate ciystals
(CaOx) were derived from 20 minute time-course measurements of 0D620
after mixing solutions containing CaCl2 and K2C204 at 37°C, pH 5.7, ionic
strength (IS) 0.21 and constant stirring (500 rpm); final assay concentra-
tions were 4.25 m calcium and 0.5 mivi oxalate, respectively. The
maximum increase of 0D620 with time, named SN, reflects maximum rate
of formation of new particles and thus ciystal nucleation. After equilib-
rium has been reached, 0D620 progressively decreases despite ionized
calcium staying constant, and no new particles are formed, due to crystal
aggregation. This is reflected by a decrease of particle numbers on
500-fold SCM magnifications. Rate of aggregation, SA, is derived from the
maximum decrease of 0D620 with time. 5N and 5A are not independent, as
indicated by a positive correlation (r = 0.844, P = 0.0001). Among the
modifiers studied, citrate at 0.5—2.5 mM lowered both 5N and SA in a
concentration-dependent manner (P < 0.01 for all comparisons vs.
control). Chondroitin-6-sulfate at 6.25—25 mg/liter moderately lowered SN,
whereas it strongly inhibited aggregation (P < 0.01 vs. control). At
6.8—20.4 mg/liter albumin did not affect nucleation, whereas it inhibited
aggregation in a concentration-dependent manner (P < 0.005 vs. control
for all comparisons). At 40 mg/liter normal human Tamm-Horsfall
glycoprotein was a strong inhibitor, retarding SN by 77% (P < 0.002 vs.
control) and SA by 69% (P < 0.002 vs. control). In conclusion, nucleation
and aggregation of CaOx can be measured separately but not indepen-
dently in a single experiment. The system is suitable for measuring distinct
effects of crystallization modifiers.
Beta2 microglobulin (132m) supports the transport of the cellular prion
glycoprotein (PrP°) to the cell surface. G. Halabi, E. Morelon, P. Laveiy,
and R. Loertscher, Transplant Immunology Laboratory, Department of
Medicine, Royal Victoria Hospital and McGill University, Montreal, QC,
Canada. Immunoprecipitation studies have shown that the natural isoform
of the prion glycoprotein (prpr) is expressed in kidneys and other solid
organs. We have previously shown that PrP° is also expressed on the
surface of mononuclear lymphocytes. Hematopoietic cell lines, with the
exception of the Daudi Burkitt lymphoma cell line, display PrP° immuno-
reactivity. The latter is characterized by a deficient beta 2 microglobulin
(I.32m) gene and an associated failure to express MHC class I molecules on
the cell surface. The present studies were undertaken to further investi-
gate the lack of PrP° on Daudi cells. PrP° is attached to the cell surface by
a GPI anchor. To rule out deficient GPI anchor synthesis we stained
Daudi cells with mAb to LFA-3 (CD58), which is also GPI anchored.
Normal LFA-3 levels were measured by FACS analysis. We further
examined the cytoplasm of Daudi cells for the presence of intracellular
PrPC. Daudi and CEM T cell membranes were permeabilized with
L-cs-phosphatidyl in 1% paraformaldehyde. Cell samples were subse-
quently stained with 3F4 mAb. Small but reproducible increases in
immunofluorescence (1.44 0.29 and 1.94 0.52; P < 0.01, Mann-
Whitney) were observed. Adequate membrane permeabilization was
demonstrated by staining for intracytoplasmic vimentin and CD3 (CEM
cells only). These results suggested a defect in PrP" translocation. There-
fore, a MHC class I positive Daudi cell variant transfected with the murine
132m gene was probed with 3F4 mAb. By FACS analysis high levels of PrP°
were detectable on transfected but not mock transfected Daudi cells. We
conclude from these results: (1) that Daudi cells have a functional PrP°
gene; and (2) that PrPC transport to the cell surface requires normal 2m
expression. It remains to be shown whether PrP° and 132m are associated
on the cell surface.
Cellular prion protein (PrP) clusters with 132 microglobulin (fJ2m) on
the cell surface of human lymphocytes. R. Loertscher, P. Laveiy, M White,
and A.!. Lazarovits, Transplant Immunology Laboratory, Department of
Medicine, Royal Victoria Hospital and McGill University, Montreal, QC; and
Robarts Research Institute, University of Western Ontario, London, ON,
Canada. We have shown that PrP° cell surface expression requires the
coexpression of f32m. In the present study we examined whether both
molecules are located in close proximity on the cell surface. We applied
the method of fluorescence resonance energy transfer (FRET) by FACS,
which measures energy transfer between the fluorochromes FITC and
TRITC provided the intermolecular distance does not exceed 10 nm. Mab
OKT11 (CD2), 7G5 (CD7), and 3F4 (PrP°) were used as FITC conjugates;
mAb 2D1 (CD45), BBM1 (32m), and W6/32 (MHC class I) were used as
TRITC conjugates. CEM T cells were simultaneously labeled with mAb to
the following pairs of determinants: CD7/CD45, CD2/CD45, PrPC/CD45,
PrP°//32m and PrPC/MHC class I. A relevant enhancement of sensitized
TRITC emission, that is transfer of energy, was observed in the PrPc/j32m
(282%), PrP°/class I (38%) and CD7/CD45 (18%) combinations. The
results for CD2/CD45 were unequivocal; no energy transfer occurred
between PrP° and CD45. Given the high copy number of CD45 cell
surface molecules, the energy transfer between PrPC and 132m and MHC
class I, respectively, cannot be explained with random clustering of PrP°
with these molecules. Neurons express PrP° at highest density, yet are
reported to lack MHC class I expression on the cell surface, which
seemingly contradicts our hypothesis. Therefore, a single cell suspension
of neurons was prepared from surgically excised human brain tissue and
analyzed by two color flow cytometry. Neurons expressed PrPC at high
level, and all PrP" positive cells coexpressed 2m and class I molecules.
The same cells also reacted with mAb to Thy-i and NCAM-i, thus
confirming the neuronal origin. From these results we conclude: (1) that
PrP° clusters with f32m and MHC class I heavy chains on the cell surface;
and (2) that the coexpression of PrP° and 132m occurs in neuronal and
extra-neuronal tissues.
Tubular reabsorption of phosphate: From physiology to pathophysiol-
ogy. Heini Murer, Institute of Physiology, University of Zurich, Zünch,
Switzerland. The renal proximal tubule reabsorbs phosphate (P1) by a
sodium (Na)-dependent secondary active transport mechanism, involving
apical Na/P1 cotransport(s). Using the Xenopus laevis oocyte expression
system, we have recently isolated from kidney cortex (different species)
and OK cell cDNA libraries two different Na/P1 cotransporters (type I and
type II). The corresponding mRNAs and proteins could be located
exclusively within proximal tubules and there in brush border membranes.
Na/P1-cotransporters have been extensively characterized functionally
after expression in Xenopus laevis oocytes (type I and II) and/or after
transfection into MDCK cells (type I) as well as insect Sf-9 cells (type II).
Thereby, transport properties (P1 kinetics, Na kinetics) resemble proper-
ties known from previous studies with brush border membrane vesicles.
Electrophysiological analysis of the type II transporter expressed in
oocytes documents that the stoichiometry (Na : P) is at least 3 and that
monovalent as well as divalent P are accepted by this transporter. The
type II (NaP-2; rat) cotransporter contains several consensus sites for
N-glycosylation. Using site directed mutagenesis we could show that two
of them (extracellularly located) are used and that the state of glycosyla-
tion does not alter transport function. Similarly, the type II cotransporter
contains several protein kinase C consensus sites. It could be documented
that the NaP1-2 transporter is indeed phosphorylated and that NaP-2
related transport function in oocytes and in Sf9-cells is inhibited by
pharmalogical activation of protein kinase C but not of protein kinase A.
At present it is not known which of the consensus sites is involved in such
regulation. Type II related transport function is also regulated at the
mRNAlprotein level. We have found that mRNA and protein content
(type II) is altered in response to P deprivation (acute and chronic), to
parathyroidectomy and parathyroid hormone treatment and reduced in
X-linked hypophosphatemia, in accordance with altered transport. Type
I-transporter seems not be regulated in response to a low P1-diet. We
conclude that mammalian renal brush border membranes contain at least
two structurally different Na/P1 cotransporters. We speculate that type I is
a constitutive (not regulated activity), whereas type II is a target for
(patho-) physiological regulations.
Furosemide inhibits lljJ-hydroxysteroid dehydrogenase in vitro and in
vivo. K V Meyer, G. Escher, B.S. Vishwanath, B.M. Frey, and F.J. Frey,
Abteilung für Nephrologie, Departement Medizin, Universitatsspital Bern,
Bern, Switzerland. 1i13-hydroxysteroid dehydrogenase (11/3-OHSD) pro-
tects the non-selective renal mineralocorticoid receptor from the endoge-
neous glucocorticoid cortisol. Thus, drugs inhibiting 1if3-OHSD might
enhance urinary loss of potassium. In an attempt to find drugs inhibiting
llp-OHSD, 23 commonly used agents known to interfere with the
potassium metabolism have been screened for inhibitory effect on li3-
OHSD. Furosemide appeared as the only inhibitor. Its inhibition constant
(I() was 19.5 j.tM when kidney and 21.3 jM when liver microsomes were
used as a source of 1 ifl-OHSD. The type of inhibition was competitive.
For confirmation that furosemide specifically inhibits i13-OHSD, the
eDNA of 113-OHSD was transfected into COS-i cells devoid of sponta-
neous expression of 1 113-OHSD. In these cells, oxidation of corticosterone
(K = 17.4 j.sM) and reduction of dehydrocorticosterone (K = 12.5 ,tLM)
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were inhibited by furosemide. In order to establish whether this inhibition
also occurs in vivo, the 11/3-hydroxysteroid prednisolone was administered
with and without furosemide to rats. The concentration ratio of pred-
nisolone to its li-ketometabolite prednisone increased in kidney and liver
tissue after furosemide administration, indicating inhibition of 11f3-
OHSD. These data suggest that furosemide modulates in vivo the access
of 11(3-OH glucocorticoids to their target organs.
Effect of angiotensin II on renal hemodynamics and glomerular per-
meability characteristics in humans. F. Steinhäuslin, T. Hannedouche, F.
Schmitt, B. Lacour, and J.-P. GilAnfeld, Division of Nephrology, Universi-
tdtsspital, Zurich, Switzerland; and Department of Nephrology, Hôpital
Necker, Paris, France. Indirect evidence suggests that the renin-angiotensin
system may be involved in the development of glomerular proteinuria in
kidney diseases. In humans, the permeability characteristics of the gb-
merular filtration membrane can be inferred from the fractional clearance
of dextrans of different molecular radius. The "isoporous with shunt"
model described by Deen et a! allows isolation of the influence of
hemodynamic factors from that due to intrinsic selectivity of the glomer-
ular capillary wall. Parameters estimated from the fractional dextran
clearances and which describe the permeability characteristics of the
glomerular filtration barrier are AP, the transmembrane pressure gradi-
ent, Kf, the permeability coefficient of the barrier, r0, the size of the barrier
restrictive pores and w0, which characterizes the "shunt" pathway through
non-restrictive pores. The effect of angiotensin II (Ang II) was studied in
eight young healthy volunteers, aged 24 to 36 years. Clearance periods
were performed at baseline and during Ang II infusion at the rate of 2.5
ng min1 . kg. Glomerular filtration rate (GFR) and renal plasma flow(RPF) were measured by inulin and PAH clearance. Glomerular perme-
ability barrier was estimated by dextran 40 clearance. Tubular handling of
sodium was assessed by the fractional excretion of sodium (FENa) and of
exogenous lithium (FELl). Mean arterial blood pressure was measured at
10 minute intervals. Ang II produced the following changes (mean SD):
Baseline Ang II
MAP mmHg 87±4 98±9
GFR mI/mm 109 12 103 7
RPF ml/min 613 168 440 76
FEN, % 2.3 0.9 1.6 0.9
FELl % 33±10 22±5
AP mmHg 30±2 38±6
Kf
r0
mmflg'ml'min
A
27±14
54±1
14±7
56±2
w, 0.12 0.04 0.14 0.08
The fractional clearances of dextrans over the whole radius interval were
significantly elevated above the baseline measurements. The model sug-
gests that Ang II exerts a negligible effect on both restrictive and
nonrestrictive pores and that the increased filtration of dextrans results
mainly from the disproportionate decrease of RPF compared with that of
GFR. These results are in agreement with the effect of Ang II on
gbomerular barrier in normal subjects aged 55 to 70 years, reported by
Loon et a!. The enhancement of sodium reabsorption appears, as previ-
ously reported, to be predominantly located in the proximal tubule.
Reduced sodium-stimulated activity of lymphocyte Na/H antiporter
in calcium renal stone formers (SF) with severe hypocitraturia (HYPO-
CIT). B. Hess, R. Takkinen, S. Shaw, and Ph. Jaeger, Medizinische Univer-
sitatspoliklinik, Inseispital, Bern, Switzerland. Intracellular acidosis in prox-
imal tubular cells is considered to be the common denominator for
HYPO-CIT. We indirectly tested this hypothesis in studying peripheral
lymphocytes (Ly) and erythrocytes (Eiy) of 9 healthy controls [C, 6 , 3
9, 43 3 years (mean SEM), U x V> 565 mg/day] and 7SF (5 ,
2 9, 35 3 years) with severe idiopathic HYPO-CIT (U1 X V < 210
mg/day) after an overnight fast. Ly were isolated from heparinized blood
after centrifugation on a Ficoll density gradient, and Ery were washed 3
times in 150 m choline-Cl, pH 7.2. Basal K in Eiy (1(i) and pH in Ly
(pH1) were measured. Ly were then acidified by nigericin, and acid-loading
was stopped by albumin. The activity of the Na7H antiporter was
estimated from max. A pH1/time (ApH1/min.) after resuspension of Ly in
NaCI (40 mM). Plasma K was 3.86 0.04 mmol/liter in SF and 4.34
0.07 mmol/liter in C (P = 0.0001), and K1 was 79.1 2.1 mmol/liter in SF
and 85,5 2.4 mmol/liter in C (P = 0.133), respectively. Basal pH was
7.21 0.03 in SF and 7.23 0.01 in C (NS). In SF, A pH1/min. was 0.62
0.06 vs. 0.83 0.03 in C (P = 0.004). In SF and C together, U1 x V
correlated with plasma K (r = 0.86,P = 0.0003) as well as with pH1/min.
(r = 0.70,P = 0.011). A pH1/min. positively correlated with plasma K (r =
0.76, P = 0.001) and with I( (r = 0.54, P = 0.037). In SF, total number of
stones ever formed was inversely related to ApH1/min. (r =
—0.76, P =
0.047). In conclusion, basal pH1 is similar in C and SF; in SF, however,
activity of the Na7H antiporter in acidified Ly is reduced upon Na°
stimulation. This appears to be related to K-depletion in SF with
HYPO-CIT.
Evidence for a role of mitogen activated protein kinase (MAPK) in the
stimulation of Pi transport by IGF-1 in renal epithelial cells. G. Palmer,
J.P. Bonjour, and .1. Caverzasio, Division de Physiopathologie Clinique,
Département de Médecine, Hôpital Cantonal Universitaire, Genève, Switzer-
land. In vivo, IGF-1 selectively enhances renal Pi transport, renal
1,25(OH)2 vitamin D production and increases plasma Pi. In confluent
opossum kidney (OK) cells in culture, IGF-1 stimulates sodium dependent
Pi transport across the apical plasma membrane. Previous studies indi-
cated that vanadate, at doses known to inhibit tyrosine phosphatases,
mimicked the effect of IGF-1 on OK cells and suggested an involvement
of tyrosine phosphorylation (TyrP) processes in Pi transport regulation.
Changes in cellular protein TyrP patterns induced by IGF-1 were thus
investigated by immunoblotting with an anti-phosphotyrosine antibody.
TyrP of p95 (type 1 IGF receptor f3 subunit) was rapidly and markedly(5.2-fold) increased upon addition of iO M IGF-1. Associated with the
phosphorylation of the receptor, changes in TyrP of several other proteins
could be recorded. Proteins phosphorylated within 1—5 minutes following
addition of IGF-1 included p65, three proteins between 56 and 53 kD, p48
and p44. Another subset of proteins, among them p170, p75 and p35, were
phosphorylated with slower kinetics. Using specific antibodies, one of the
tyrosine phosphorylated proteins was identified as MAPK-p44. A transient
increase in TyrP of p44 MAPK was observed during the first 15 minutes
following addition of IGF-1. This suggests a transient activation of this
serine/threonine kinase in response to IGF-1. Vanadate did not influence
the TyrP of the IGF receptor, but mimicked the transient increase in
MAPK phosphorylation preceeding changes in Pi transport, as well as the
TyrP of several other proteins. Taken together, these data point to a role
for specific cellular Tyr phosphorylated proteins in the regulation of
phosphate transport in renal epithelial cells. They also suggest a new
function of MAPK in mediating the effect on Pi transport induced by
IGF-1 in non-proliferating, differentiated kidney cells.
The activation of protein kinase C (PKC) stimulates Na-K-ATPase in
the rat proximal convoluted tubule. E. Féraille, M. Rousselot, and H. Favre,
Hôpital Cantonal Universitaire, Genève, Switzerland. The activation of PKC
by hormones or phorbol-esters increases Na reabsorption by the rat PCT.
Since Na-K-ATPase drives virtually all Na reabsorption along the
nephron, this effect of PKC on PCT must rely on a stimulation of
Na-K-ATPase activity. In contrast, an antiphysiobogical inhibition of
Na-K-ATPase activity by phorbol-esters has been reported in the isolated
rat PCT. This inhibition of Na-K-ATPase activity was secondary to
phospholipid breakdown through the activation of phospholipase A2 and
the subsequent metabolism of arachidonic acid through the cytochrome
P450 pathway. However, these experiments were performed in the ab-
sence of oxygen supply and anoxia is known to activate phospholipid
breakdown, increase arachidonic acid metabolism, and inhibit Na-K-
ATPase activity. Therefore, we studied the effect of the oxygenation of the
tubules on the action of phorbol-esters on Na-K-ATPase ATP hydrolytic
activity in the isolated rat PCT. In oxygenated tubules, PDBU did not alter
Na-K-ATPase activity (as pmol mm1 min sE; C: 37.2 4.9;
PDBU: 37.8 4.0), whereas in anoxic PCT, PDBU iO M inhibited the
maximal hydrolytic activity of Na-K-ATPase (C: 29.6 2.7; PDBU: 20.7
0.8; P = 0.01). Thus, in the following sets of experiments, the effect of
PKC activation on Na-K-ATPase was reassessed in oxygenated isolated
rat PCT. Both PDBU and PMA stimulated the ouabain-sensitive 86Rb
uptake by 50%. This effect was dose-dependent (threshold: 10_li M and
maximal: iO M), time-dependent (significant after 10 mm of incubation
at 37°C), and prevented by preincubation in the presence of PKC
inhibitors (staurosporine and GF109203X). In addition, PDBU increased
the sensitivity of the ATP hydrolytic activity of Na-K-ATPase to Na as I(Q5
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decreased from 73.2 9.3 mat to 53.3 7.2 mat (P < 0.03) but did not
alter the Vmax of the enzyme. These results show that in the oxygenated
isolated rat PCT, the activation of PKC primarily stimulates Na,K-ATPase
by enhancing its sodium sensitivity.
Effect of plasma from children with idiopathic nephrotic syndrome on
mesangial cell proteoglycan synthesis. N. Benador, A. de Agostini, and E.
Girardin, Département de Pediatric, Hôpital Cantonal, Genève, Switzerland.
Idiopathic nephrotic syndrome (INS) still has an unclear etiology. A loss
of anionic charges (mainly heparan sulfate glycosaminoglycan) of the
glomerular basement membrane could be the cause of the proteinuria.
Immune regulation is abnormal and a lymphocyte dysfunction is suspected
with production of a circulating factor acting on the glomerulus. The
effects of this factor on proteoglycan synthesis by mesangial cells (MC) are
unknown. To study these effects in vitro, we used a model of cultured
primary rat MC. The cells were stimulated with plasma of 7 untreated
proteinuric patients with INS or with plasma of controls added at
concentrations of 2 and 5%. Total proteoglycan, chondroitin sulfate and
heparan sulfate were quantified by a solid-phase assay using a cationic
nylon blot. When exposed to 2% plasma from patients with INS, total
proteoglycans decreased by —27.5 19.2% (P = 0.128), chondroitin
sulfate decreased by —25.2 17.9% (P = 0.128), and heparan sulfate by
—18.1 28.1% (P 0.128) compared to the cells exposed to normal
plasma. When exposed to 5% plasma, total proteoglycans decreased by
—42.6 12.0 (P = 0.028) and heparan sulfate by —36.1 13.6% (P =
0.043). Heparan sulfate accounted for 36.4% of the proteoglycans se-
creted by MC exposed to normal plasma and for 47.4% when the cells
were exposed to plasma from INS patients. These data indicate that
plasma from INS patients induces a dose-dependent decrease of proteo-
glycans produced by MC. We conclude that a circulating factor in the
plasma of INS patients may induce proteinuria by directly affecting the
synthesis of proteoglycans by MC.
A defect in the aquaporine 2 water channel gene in 2 brothers with
autosomal recessive nephrogenic diabetes insipidus (ND!). E. Leumann,
J. Briner, A.F. van Lieburg, and L. Monnens, Universitdt-Kinderklinik und
Institut für Klinische Pathologie, Zurich, Switzerland, und Department of
Paediatrics and Human Genetics, Nijmegen, The Netherlands. Different
mutations in the autosomal gene encoding the water channel aquaporine
2 (AQP2) of the renal collecting duct have been reported very recently in
4 patients with the rare form of autosomal recessive NDI. We observed
NDI in 2 of the 3 sons of consanguineous parents from Sri Lanka. The
elder patient was referred at the age of 5 months because of muscular
hypotonia; serum sodium was 186 mmol/liter and urine osmolality was 173
mOsmlkg. Despite treatment with hydrochlorothiazide and tube feeding,
the patient failed to thrive and succumbed at the age of 13 months after
severe convulsions and extensive bilateral necrosis of the basal ganglia.
Instead of an X-chromosomal defect, a mutation in the AQP2 gene on
chromosome 12 was detected. Meanwhile, NDI was diagnosed in the
younger brother shortly after birth (serum sodium 149 mmol/liter and
urine 107 mOsm/kg). Thanks to early diagnosis and treatment, this patient
is at present (age 5 months) developing normally. Functional studies of the
defective AQP2 water channel are under way. Congenital NDI is geneti-
cally heterogeneous, which has implications for genetic counseling. Late
diagnosis may have disastrous consequences.
Bilateral renal cell carcinomas in patients with acquired renal cystic
disease. A clinicopathologic and DNA content analysis of 3 cases. L.
Guillou, E. Descombes, AS. Baur, F. Mosimann, P. Schnyder, and J.P.
Wauters, Institute of Pathology and Departments of Nephrology, Surgery, and
Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Acquired renal cystic disease (ARCD) develops in about 50% of patients
receiving long-term dialysis. Its prevalence and severity depend on the
duration of dialysis treatment, but not on age, nature of the original renal
disease or treatment modalities. Development of renal cell carcinoma is a
major complication of ARCD. We have observed 3 cases of bilateral renal
cell carcinoma occurring in patients with ARCD in our institution during
the last 4 years. (1) A 43 year-old man, having received hemodialysis since
he was 30 due to glomerulonephritis (GN), was admitted because of
abdominal and iliac pain. A renal transplantation had been performed at
the age of 37 but the transplant was rejected one year later. US and CT
investigations showed a mass in the right kidney. Bilateral nephrectomy
was performed and pathologic examination showed, in addition to ARCD,
bilateral clear cell carcinoma (maximal diameter: 10 and 3.5 cm) and a
renal cell microcarcinoma or "adenoma" (maximal diameter: 1.3 cm) in
left kidney. Four years postoperatively, there was no evidence of recur-
rence or metastasis. (2) A 39 year-old man, having received hemodialysis
for 5 years due to GN, transplanted at the age of 31, was admitted because
of chronic rejection, renal graft and right kidney infection, occurring in a
context of ARCD. Native kidneys and graft were surgically removed.
Pathologic examination showed, in addition to ARCD, 7 microcarcinomas
(maximal diameter: 1 cm) in the right kidney and 2 in the left kidney.
Eighteen months postoperatively there was no evidence of recurrence or
metastatic disease. (3) A woman experienced renal lithiasis at the age of
29. From then on, she progressively developed renal insufficiency and
chronic uremia. At the age of 59, after 4 months of hemodialysis, she was
successfully transplanted. At the age of 66, a mass was detected in her right
kidney and bilateral nephrectomy was performed. Pathologic examination
showed, in addition to ARCD, a clear cell carcinoma (maximal diameter:
3.5 cm) and 3 microcarcinomas (maximal diameter: 2.5 cm) in the right
kidney, as well as 2 microcarcinomas (maximal diameter: 0.7 cm) in the
left kidney. Eighteen months postoperatively there was no evidence of
recurrence or metastatic disease. Image cytometry analyses showed aneu-
ploidy in most renal tumors. These observations illustrate the preneoplas-
tic potential of ARCD. Since the incidence of renal cell tumors in
hemodialysis patients (varying from less than 1% to 10% of the cases)
appears much greater than the one observed in the general population,
yearly or bi-annually screening (including US or CT examination) is
advocated. Most of the small tumors, s 3 cm in maximal diameter
(so-called "adenomas") in our series are aneuploid and should be
considered as incipient carcinomas.
Routine urinalysis as a screening test for urinary tract infection. J.D.
Graf and P. Rohner, Division de Nephrologie et Division des Maladies
Infectieuses, Hôpital Cantonal Universitaire de Genève, Genève, Switzerland.
A retrospective study was conducted to evaluate dipstick urinalysis and
sediment examination as screening procedures for detecting urinary tract
infection: 3400 urines were analyzed using an automated dipstick tech-
nique (leukocyte esterase, nitrite), microscopic examination of the sedi-
ment (leukocyte count), as well as bacterial culture. The criterion for
urinary tract infection was a bacterial count of  10E5 colony forming
units (CFU/ml), without regard to the bacterial species involved. Urine
specimens with 10E3 CFU/ml were considered negative, whereas spec-
imens with 10E4 CFU/ml were excluded from the study. Considering
bacterial culture, evidence of urinary tract infection was found in 1125
urine specimens. Of the three screening assays evaluated, leukocyte
esterase showed the highest sensitivity (Se 0.90) and negative predictive
value (NPV = 0.91) for detecting urinary tract infection (specificity Sp =
0.61). The leukocyte count in the sediment (cut-oft value 5 leukocytes!
HPF, Se = 0.77, NPV = 0.84, Sp = 0.75) and the nitrite assay (Se = 0.59,NPV = 0.79, Sp 0.88) were less sensitive. The predictive value of
two-test combinations was evaluated. The association of leukocyte ester-
ase and nitrite showed the highest sensitivity (Se = 0.92) and negative
predictive value (NPV = 0.94) with a specificity of 0.59. These results
indicate that dipstick urinalysis (leukocyte esterase plus nitrite) is more
sensitive than leukocyte count in the sediment for predicting bacteriuria,
and provide a basis for the selection of urine specimens according to their
probability of producing a positive bacterial culture.
Influence of cyclosporine A on plasma and urine endothelin-1 in living
related kidney donors and recipients. M Zeiler, B. Loffler, A. Bock, and G.
Thiel, Kantonsspital Basel, Universitbtskliniken, F. HoJfinann-La Roche,
Basel, Switzerland. Cyclosporine A (CsA) has been reported to increase
urine endothelin-1 (uET-I) excretion. To investigate differences in uET-1
excretion and plasma endothelin-1 (pET-i) levels between patients with
and without CsA, we compared living related kidney donors, without CsA
therapy, (1(D) and their respective kidney recipients, with CsA therapy,(KR) one year after surgery. In 12 pairs of KD and KR glomerular
filtration rate (GFR, by inulin clearance), pET-i and uET-1 excretion as
well as blood pressure (BP) and CsA trough levels were measured at one
year after nephrectomy, respective of transplantation (Mean su, 391
32 days). Urinary ET-1 excretion was evaluated by a 12 hour overnight
urine collection.
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KD KR
uET-1 excretion, pg/mm 111.2 53.1 109.3 52.2
pET-1,pg/ml 26.7 4.1 31.9 8.3a
ET-1 clearance, mI/mm 4.3 2.4 3.7 2.1
GFR, mi/mm 65.0 16.8 60.3 29.4
BP systolic, mm Hg 133 16 146 19
B? diastolic, mm Hg 83 12 86 7
Mean SD (N = 12) P < 0.05 Wilcoxon matched pairs test
CsA trough levels in KR were 199 113 ng/ml (range 59—471 ng/ml); CsA
was applied twice daily at a total dose of 4.3 1.5 mg/kg/day (range
1.9—6.6 mg/kg/day). Patient age was 51 14 years in KD and 44 11
years in KR. Significant differences between KD and KR were found
regarding elevated pET-I levels and systolic BP in KR. In 11 of 12 KR and
in 1 of 12 KD, antihypertensive therapy (ACE-inhibitors, Ca-antagonists,
13-blockers or diuretics) was given. In conclusion, we did not find any
evidence that CsA therapy increases uET-1 excretion in kidney recipients.
The coincidence of significantly elevated pET-i and systolic BP in KR
suggests a possible systemic role of ET-1. The influence of antihyperten-
sive treatment on uET-1 excretion and pET-I remains to be investigated.
Extracutaneous Kaposi sarcoma after renal transplantation: Course
after discontinuation of immunosuppression in two cases. M Bianchetti,
P. Itin, T Gasser, A. Bock, M Mihatsch, and G. Thiet, Departemente Innere
Medizin, Dermatologie, Chirurgie und Pathologie, Kantonsspital und Univer-
•cität Basel, Base!, Switzerland. The incidence of Kaposi sarcoma (KS) after
renal transplantation was reported to vary from 0.4—4.1%. We are
presenting two cases among all the 573 renal transplants, who survived
longer than 2 years with a functioning graft (0.3%). In both cases, the
localization was only or also extracutaneous, when the diagnosis was
made. Case one: A 34 year old male (chronic glomerulonephritis cGN)
received a cadaveric renal transplant (T) in October 1985 and was initially
immunosuppressed with cyclosporine A (CsA), prednisone (P) and ATG.
He had one single rejection therapy of 6 x 0.5 g methylprednisolone
during the first months, and 4.7 years after T he developed dysuria,
intermittent macrohematuria and lower abdominal pain while on CsA
monotherapy. Cystoscopy revealed a peculiar tumor, which was removed
by transurethral resection. Histology revealed a Kaposi sarcoma. Immu-
nosuppression (IS) was reduced (CsA 3.5 mg/kg/day — 2.3 — 1.4).
Because of persisting micturition problems, macrohematuria and enlarge-
ment of bladder wall on computer tomography, IS was totally stopped 7
months later (February 1991), and dialysis resumed. He died in February
1993 due to cardiac arrest. On autopsy KS had totally disappeared. Case
two: A 41 year old male (cGN) received a cadaveric renal T on September
1991 and an IS with OKT3, CsA, Azathioprin (Aza) and P. Because of
severe rejection he was treated with OKT3 retherapy (total OKT3 dose: 70
mg), which was followed by three other rejection episodes, leading to a
total of 15 methylprednisolone pulses (0.5 g each). Renal function
recovered (stable p-creatinine at 160 jimol/liter). At our yearly routine
checkup (September 1993) the dermatologist detected large KS on the
roof of the mouth (palate) and on the skin (back, abdomen, one leg).
CsA-Aza-dual therapy was reduced to CsA monotherapy (November
1993). Since regression was seen orally only, CsA was stepwise tapered
(3.8 mg/kg/day —* 1.5 mg). Instead of regression, fever and rapid lymph-
adenopathy and splenomegaly occurred in March 1994. Since histology
revealed KS in both, IS was totally stopped, and spleen and graft were
removed. While on dialysis, the patient died in June 1994 (9 months after
KS diagnosis and 3 months after total discontinuation of IS) by intestinal
bleeding due to KS in the jejunum. At autopsy, KS had diffusely infiltrated
in the lung and lymphatic system. Retrospectively, we have lost 6 months
after diagnosis of extracutaneous KS until total discontinuation of IS
because of the tapering concept. Conclusions: Tapering IS alone in
extracutaneous KS can be dangerous. We recommend a rapid total
discontinuation of IS when the extracutaneous localization of KS is
documented.
Socio-economic urgency score for cadaveric renal transplantation: First
experience in Basel. R. Honegger, M. Spoendlin, H.A. Bock, and G. Thiel,
Abteilung für Nephrologie, Kantonsspital Base4 Base4 Switzerland. There is
an enormous discrepancy between the availability and demand for cadav-
eric kidneys. Until now kidneys were allocated on a "first come, first
served basis" to patients on the Basel waiting list without regard to HIA
matching, except for a clearly defined immunological risk group. This
allocation, although fair, is often not satis1ing. For example, a 70-year-old
pensioner would receive a renal transplant if it was "his turn," whereas a
younger father would not receive the kidney if his name was not next on
the list, even though a successful transplantation (tx) could save his job. In
order to overcome this unsatisfactory situation, an urgency score (USc)
has been designed and tested (for the time being just to gain experience)
without using it for graft allocation. The score includes the following
items: age, present working ability/housekeeping, expected working ability
after tx, household with children under 12 years old, objective problems at
dialysis, compliance, symptomatic heart disease, arterial occlusive disease,
and cerebrovascular disease (depending on disability grade). The highest
possible score is 62. A theoretical cut-off score of 31 was defined resulting
in two patient groups: group A 31 (N = 16), group B <31 (N = 13).
Seven centers participated (Aarau, Baden, Basel, Liestal, Luzern, Porren-
truy and Solothurn). In addition to the USc a questionnaire including
working ability and housekeeping after tx as well as physical/psychical
well-being and social integration was completed by all transplanted
patients. Statistical analysis was performed using the Mann-Whitney test.
Results: Since December 1993, 88 scores are available on the waiting list
[34 8 (mean SD) ranging from 12—53]. From January to September
1994 (deadline = 14.9.94) 33 kidneys were transplanted to recipients with
a score of 32 7 (range 20—46). Four patients lost their graft due to
rejection/infection (1 of group A, 3 of group B). With respect to
comparable follow-up days in both groups (153 65 days in group A
versus 175 81 in group B, deadline = 1.11.94) the following results were
available: group A presented with a score of 38 5 while a score of 25
2 was found in group B (P < 0.05). The patients in group A were
statistically significantly younger than those in group B: 46 11 versus 63
7 years (P < 0.05) while there was no difference in sex ratio (group A:
7 M:9 F, group B: 8 M:5 F). No differences were found in duration of first
hospitalization (group A 26 10 vs. group B 26 9 days), in total
hospitalization days including rehospitalization due to adverse events
(group A 32 14 vs. group B 35 15), and rehospitalization per patient(group A 0.75 0.86 vs. group B 1.00 1.00). Also comparable were
kidney function (serum creatinine in group A 122 49 .rmol/liter versus
109 47 in group B), housekeeping, physical and psychical well-being and
social integration. Group A presented with a slightly better working ability
(WA) after tx: 0% WA before tx = 10/16 patients versus 7/16 after tx, 2/16
patients > 50% WA before tx versus 5/16 patients after tx. Contrary to
group A the patients of group B presented with a comparable WA before
and after tx as 12/13 patients did not work (0% WA) before tx versus 11/13
after tx and 1/13 patients presented with 50% WA before tx versus 2/13
patients after tx. Conclusion: The limited follow-up time does not allow us
to decide whether the use of such an Use could be recommended (we
rather doubt!). However, as it is a reasonable attempt to objectively assess
"socio-economic" urgency, further long-term results are required to
establish a consensus between participating centers.
Cadaveric renal transplants functioning over 20 years. H.R. Raz, HA.
Boc/ç, F. Enderlin, F. Harder, and G. Thiel, Departemente Innere Med izin
und Chirurgie, Kantonsspital und Universitat Base!, Base!, Switzerland.
Ninety-three cadaveric renal allografts transplanted from 12.7.67 until
10.9.74 have been functioning for over 20 years. We evaluated them for:
(1) actual graft and patient survival; (2) the quality of renal function; (3)
the quality of life of the surviving patients; and (4) for parameters which
could have predicted long-term success (>20 years) already at the end of
the first year after transplantation. Results: (1) Actual graft and patient
survival at 20 years was 11% (10/93) and 13% (12/93). (2) At 20 years
mean plasma creatinine was 97 26 i.tmol/liter (range 81—135), mean
proteinuria 0.40 0.70 g/day (range 0.07—1.71), mean creatinine clearance
83 29 mI/mm (range 44—116), mean blood pressure 127 8/81 8
(range 115—140/70—90), and mean number of antihypertensive and di-
uretic drugs 0.9 0.8 (range 0—2). All were on azathioprine (1.21 0.47
mg/kg/day) and prednisone (0.14 0.03 mg/kg/day). (3) Quality of life was
excellent in all survivors, despite coronary heart disease in two (treated by
aortocoronary bypass in one), lymphoma in one (treated successfully by
splenectomy and chemotherapy), peripheral arterial occlusive disease in
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one (treated successfully by ileofemoral dacron bypass), allograft-artery
stenosis in one (treated by PTA), femoral head necrosis in two (treated by
total hip replacement, complicated in one patient by salmonella dublin
infection of the hip prosthesis, successfully treated by antibiotics) and skin
cancer in 4 (40%, treated in all cases by excision, one out of them a
malignant melanoma successfully treated by surgery alone). Disability
pension was paid 100% to one patient, despite his working in his own
business and 50% to another after myocardial infarction in 1982. All
others were working 100% in their learned profession. (4) If compared to
the control group of 83 cadaveric renal allografts transplanted longer than
20 years ago but had failed (or died) before 20 years, age at transplanta-
tion was significantly lower in the success group [32 8 years (range
20—47) vs. 40 10 years, (range 20—59); P < 0.02], but male preponder-
ance was not (80% males vs. 55%, P = NS). Neither HLA-A/B-
mismatches (1.4 1.0 vs. 1.4 0.8), plasma creatinine at day seven (264
242 mmol/liter vs. 336 234 mmol/liter; P = NS), plasma creatinine at
one year (94 19 mmol/liter vs. 119 63 mmol/liter; P = NS) nor
proteinuria at one year (0.56 0.66 g/day vs. 1.11 1.83 g/day; P NS)
were significantly different from each other. Conclusions: (1) Although
only about 10% of cadaveric renal allografts transplanted before 1974
were still functioning 20 years later, the quality of life, professional
rehabilitation and renal function were remarkably good. (2) No parameter
reliably predicted long-term success within one year after transplantation.
Incidence of malignant tumors after kidney allotransplantation: Single
center study in 1,682 patients. D. Holy, F. Steinhduslin, and U. Binswanger,
Division of Nephrology, Departement Internal Medicine, University Hospital,
Zurich, Switzerland. The incidence of tumors is elevated in transplant
(TPL) patients, and cancer (Ca) remains an important cause of death in
these patients. Since the introduction of cyclosporine A (CsA) in the
immunosuppressive regimen, the distribution of the type of Ca appears to
have changed. The use of antilymphocyte sera (AL) has been associated
with an increased incidence of lymphoproliferative tumors. We have
retrospectively analyzed the incidence of malignant tumors in our collec-
tive of 1682 patients transplanted since 1964. Between 1964 and 1984
(regimen A: 817 patients) basis immunosuppression consisted in azathio-
prine (Aza) and prednisone (Pred). Since 1984 (regimen B: 865 patients),
CsA was added. AL sera were used for either induction therapy or the
treatment of steroid-resistant acute rejection episodes. The cumulative
incidence of malignant tumors was 2.44% (41 Ca in 39 patients), with a
majority of mucocutaneous tumors. Cancer was the cause of death in 11
patients. Lymphoproliferative disorders were found in 6 patients, 2 of
whom had been treated with AL. The table summarizes our results:
Type of tumor
Regi
A
men
B
Age
at Ca
Years
after
TPL
Years
follow-up
after Ca
Patients
deaths
Mucocutaneous cancer 7 9 49.9 7.8 4.6 3/13
Urothelioma 2 2 53 8.5 2.8 2/2
GIT cancer 1 3 62.8 7.3 2.5 1/4
Breast cancer 1 1 45.5 4 8 0/2
Lymphoproliferative 0 6 55.5 5.1 2 3/6
disorder
Kaposi sarcoma 0 2 45.5 0.6 6.5 0/2
Prostate carcinoma 2 0 65 14.5 4.5 0/2
Lung carcinoma 1 2 58.7 8.7 0.7 3/3
In addition, six other patients had malignancy prior to TPL (time to TPL
4.5 years). There is no evidence of recurrence of malignant disease at the
time of follow-up (2.5 years). The incidence of malignant tumors found in
our collective of 1682 kidney transplant patients is comparable to that
reported in Europe.
Quantitation of proteinuria in kidney transplant patients: Accuracy of
the urinary protein/creatinine ratio. F. Steinhduslin and J. -P. Wauters,
Division of Nephrologv, Centre Hospitalier Universitaire, Lausanne, Switzer-
land. The follow-up of renal function in kidney transplant (KTPL) patients
requires sensitive and specific parameters which allow the detection of
clinically significant changes. Quantitation of proteinuria is customarily
expressed as the 24-hour protein excretion (P24), which requires precisely
timed and measured urine collections. In native kidney diseases, the urine
protein to creatinine ratio (Ur,IUcr), measured on spot urine samples,
appears to be a reliable estimate of the degree of proteinuria. This
prospective study was undertaken to assess the accuracy of Ui,/Ur in
estimating P24, and its utility in the follow-up of proteinuria in patients
with different immunosuppressive regimens, including or not corticoste-
roids. Over a 4-month study period, 133 patients provided 520 timed and
measured urine collections and the corresponding morning urine samples
(7—9 am.). Median time after KTPL was 38 months (1—193). Plasma
creatinine was 142 /.Lmol/liter (73—417), creatinine clearance 60
ml min' - 1.73 m2 and P24 0.24 g 24 hr1 1.73 m2 (0.02—12.1). The
correlation coefficient of U,/Ur versus P24 was 0.93 (P < 0.001) in both
the first set (N = 133) and in the whole set (N = 520) of paired samples.
The predicted P24, calculated as (U1,/Ur) (24 hr creatinine excretion),
was in good agreement with the measured P24 (N = 520; r = 0.93, P <
0.001). The detection limit of U1,/U, and its specificity and sensitivity at
different levels of proteinuria was determined using the ROC curve
technique, and are summarized in the following table (samples with 24 hr
creatinine excretion 8000—14000 mol -24 hr1 1.73 m2; N = 318):
Proteinuria
(g 24 hr' 1.73 m2) 0.25 1.0 2.0 3.5
Detection limit g/mol 24 80 210 290
specificity % 95 99 98 97
sensitivity % 97 98 99 99
In the whole set of 520 samples, specificity was 86 to 94% and sensitivity
93 to 99% for the same detection limits. Dipstick assessment of protein-
uria was 59—77% specific and 91—99% sensitive. Repeated samples were
provided by 82 patients (442 samples). Intraindividual CVs of P24 and
Up!Ucr were 23 and 29%, respectively. CV of the dipstick method was
17%. In conclusion, in KTPL recipients, the U1,/U. measured in spot
morning urine samples is a reliable estimate of P24 and its variation
accurately reflects changes of P24 over time.
E. coli-derived lipopolysaccharides (LPS) and TNF-a induce similar
injuries in glomerular endothelial cells (GEC); however, only LPS effects
depend on the presence of active serum. V Briner, Ch. v. Grinigen, and R.
Landmann, Departement Medizin, Universitätskliniken, Bern and Basel,
Switzerland. Acute renal failure is a complication of gram-negative sepsis.
In rabbits endotoxemia elicits effects within 5 minutes after LPS injection.
First morphologic changes occur in GEC. Endotoxemia also leads to high
blood levels of TNF-a, which is believed to be a major pathogenetic factor
for organ failure in septic shock. LPS-induced effects in pulmonary EC
have been shown to depend on the glycoprotein CD 14. Two forms of
CD14 exist, the membranous form on myeloid cells and the soluble form
which is found in normal serum. Aim of the present study. To compare
LPS and TNF-a effects in bovine GEC and to investigate the mechanism
by which cytotoxicity (assessed by Trypan blue staining) is induced. Both
LPS and TNF-a exposure for 24 hours caused GEC death in a dose-
dependent manner (control: 57 1 X io cells alive/well 100%; LPS 1
ng/ml 98 7%; 10 nglml 48 2%; 100 ng/ml 36 4%; TNF-a 1 ng/ml
97 2%, 10 ng/ml 83 4%; 100 ng/ml 43 2%). LPS-mediated toxicity
required the presence of complete serum. Incubation of GEC with
medium supplemented with nutrients but with albumin instead of serum
resulted in cell death (5% serum 23 1 >< iO cells alive/well = 100%; 5%
albumin 25 3%). Heat pretreatment of the serum (60° for 30 mm)
attenuated LPS-induced effects; however, it did not affect TNF-cs-induced
cytotoxicity [control 39 1 x io cells alive/well = 100%, 10 ng/ml LPS
38 3%, 10 ngjml TNF-cs 77 2%; heat treated (ht) control 103 2%;
ht + LPS 61 2%, ht + TNF-a 73 3%]. LPS effect was abolished by
pretreatment of GEC with medium supplemented with a monoclonal
antibody (3C10) directed against soluble CD14 (control 100%, LPS 31
1%, LPS + 3C10 96 4%), but not by a control mouse monoclonal IgG
(30 2%). TNF-a effects were prevented by a monoclonal antibody
against TNF-a (control 100%, TNF-a 57 3%, TNF-a + anti-TNF-a 94
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6%). Summary: In GEC LPS and TNF-a elicit similar cytotoxicity. The
mechanism by which these effects are mediated, however, is different. LPS
effect is induced via soluble form of CD14 while TNF-a effect did not
depend on active serum. These findings may be important for new and
diverse treatment strategies in gram-negative sepsis.
Impaired growth in children with mild proximal renal tubular acidosis.
MS. Ghuysen, J. Pelet, and f-P. Guignard, Service de Pédiatrie, CHUV
Lausanne, Switzerland, Failure to thrive is commonly associated with the
presence of chronic metabolic acidosis. Retention of fixed acids or
bicarbonate wasting can both cause metabolic acidosis. The aim of this
study was to evaluate the effect of mild proximal tubular acidosis (RTA)
on growth, and its response to alkali therapy. Nineteen infants (mean age
21 months) presenting with failure to thrive were investigated. Additional
symptoms were anorexia (52%), vomiting (25%), and polyuria (5%).
Growth retardation was —1.48 0.86 SDS for height with a weight for
height ratio of 85.8 6.5%. The infants were found to have a mean
plasma bicarbonate concentration of 17.5 5.0 mmol/liter. Specific
acidification tests, including the response to an acute acid load, the
determination of the bicarbonate threshold, and the urine minus blood
PCU2 (APCO2) during alkaline diuresis were performed. The diagnosis of
proximal RTA was based on the following findings: renal bicarbonate
threshold 17.0 2.1 mmol/liter; APCO2, 19.5 0.2 mm Hg; normal
ammonium and titratable acid excretion. Calcium excretion was normal
(0.48 0.38 mol Ca/mol creatinine). To achieve normal plasma bicarbon-
ate levels, these infants required 4.2 2.8 mmol/kg per day of sodium
bicarbonate. During the 4 years following diagnosis, height and weight
were measured at 3 month intervals. The following changes in height SDS
and weight for height were recorded: —0.88 0.91 and 86.6 7.0% at 1
year; —0.79 0.74 and 90.0 5.5% at 2 years; —0.53 0.78 and 91.5
5.4% at 3 years; —0.06 0.76 and 93.2 6.0% at 4 years. We conclude:
(1) that mild idiopathic proximal RTA impairs growth significantly, in the
absence of retention of fixed acids; (2) that the presence of occult proximal
RTA should be looked for whenever failure to thrive is present in a child;
and (3) that appropriate alkali therapy in these children results in
progressive catch-up growth.
Effect of the calcium channel blockers diltiazem (DTZ) and felodipine
(FDP) on calcium-phosphate metabolism in patients with end-stage renal
disease (ESRD). K Lippuner, H-f Zehnder, f-P. Casez, R. Takkinen, C.
Descoeudres, and Ph. Jaeger, Medizinische Universitatspoliklinik, Bern,
Switzerland. After EDTA-induced hypocalcemia, healthy volunteers
treated with diltiazem (DTZ) display more severe hyperparathyroidism
(HPTH) than subjects on felodipine (FDP) studied under identical
conditions. Therefore, patients with ESRD and severe secondary HPTH
might be particularly sensitive to this side-effect. To test this hypothesis, 7
patients with ESRD on chronic hemodialysis (HD) were studied both
before and during the first 180 minutes of HD against a dialysate with low
calcium concentration (0.75—1.0 mmol/liter) under 3 experimental condi-
tions: after 2 weeks without any calcium channel blockers (0), after 2
weeks on FDP (10 mg/day), and after 2 weeks on DTZ (120 mg/bid.).
Washout period was 2 weeks. Daily intakes of phosphorus as well as of
phosphate binder (CaCO3) were kept unchanged throughout the study.
Serum values at onset of HD are given in the table.
0 DTZ FDP
Phosphate, rnss 1.88 0.16 2.03 aos" 1.64 O.lO'
Calcium, mM 1.17 0.01 1.14 0.02C 1.20 0.03
iPTH,pg/ml 305 49 324 47 246 55
1,25(OH)2D3, pg/ml 3.87 0.62 6.70 0.92a 4.75 0.91
a P < 0.05 vs. CU, b P< 0.02 vs. CU, C P < 0.05 vs. FDP, d P < 0.02 vs.
FDP (Wilcoxon signed rank test). Mean 5CM.
During dialysis sessions, serum P was higher (P = 0.0001),Ca' was lower(P = 0.0001), and iPTH was higher (P = 0.0001) on DTZ than on FDP
(ANUVA for all time points: 0, 15, 30, 45, 60, 90, 150, 180 mm), with
intergroup differences which progressively decreased over dialysis time.
The area under the curve "PTH" versus "first 60 mm of HD" was higher
by 16 7% on DTZ than on FDP (P C 0.05). Conclusion: ESRD patients
have higher basal serum P levels on DTZ than on FDP despite identical
intakes of P as well as of phosphate binders. During HD the degree of
severity of HPTH induced by low calcium dialysis is higher on DTZ than
on FDP. The mechanism of relative hyperphosphoremia on DTZ as well
as the long-term clinical significance of this observation remain to be
evaluated.
Nitric oxide regulates GFR and RBF in newborn rabbits. L. Ballhvre, M.
Thonney, and J.-P. Guignard, Service de Pédiatrie, CHUJç Lausanne,
Switzerland. Nitric oxide (NU) is a potent soluble vasodilator released by
the vascular endothelium. The role that NU may play in regulating the
immature kidney microcirculation was investigated in 17 anesthetized and
mechanically-ventilated newborn rabbits. Renal blood flow (RBF) and
glomerular filtration rate (GFR) were assessed by the standard clearance
of inulin and PAH, respectively. Arterial blood pressure and heart rate
were continuously monitored. Each animal acted as its own control. In a
first group of 9 animals (aged 6.1 0.3 days; body weight 115 4 g), the
NU synthesis inhibitor L-NAME (N°-nitro-L-arginine methyl ester) was
administered i.v. at a dose of 50 jig - kg1, followed by 10 jrg kg' min1
to determine the role of NU in regulating renal hemodynamics in newborn
rabbits. The protocol included a control clearance period and 3 subse-
quent experimental periods after the infusion of L-NAME. At this dose,
L-NAME did not modify mean arterial pressure or pulse rate. Urine flow
rate remained constant, while the renal vascular resistance increased
progressively by 31 3% (P C 0.01). RBF decreased concomitantly by 20
6% (P C 0.01). A delayed decline in GFR was observed, which only
became significant (13 5%; P C 0.05) 90 minutes after administering
L-NAME. The filtration fraction increased by 8 5% (P C 0.05). In a
second group of 8 animals (aged 7.0 0.6 days; 124 5 g) also receiving
L-NAME with the same protocol as in group 1, L-arginine was adminis-
tered during the last period at a dose of 1 g - kg', followed by 1 mg -kg1
min1. This group was used to demonstrate the ability of L-arginine, the
physiological precursor of NU synthesis, to prevent the effects induced by
L-NAME. After giving L-arginine, the increase in RVR and decrease in
RBF induced by L-NAME were partially reversed. These results indicate
that: (1) NU participates in the regulation of the immature kidney renal
hemodynamics in basal conditions; (2) NU synthesis inhibition by L-
NAME results in a arteriolar vasoconstriction that predominates in the
efferent arterioles; (3) the effect of NU synthesis inhibition by L-NAME
can be partially reversed by administering a NU precursor. We conclude
that NU plays a significant role in maintaining the perfusion of the
immature kidney in normal conditions, primarily by decreasing the
afferent and efferent arteriolar resistances, without altering systemic
arterial blood pressure.
Physiological changes of plasma and urine endothelin-1 before and
after unilateral nephrectomy in humans. M. Zeiler, B. LoftIer, A. Bock, and
G. Thiel, Kantonsspital Basel Universitatskliniken, F. Hoffinann-La Roche,
Basel, Switzerland. Endothelin-l (ET-1) is assumed to play an important
role in renal pathophysiology after unilateral nephrectomy (Nx). We
therefore studied alterations in plasma ET-l (pET-i) levels and urine
ET-1 (uET-1) excretion in living related kidney donors (1(D) before and
after Nx. In ten lCD pET-i, uET-1, glomerular filtration rate (GFR, by
inulin clearance) and renal plasma flow (RPF, by PAH clearance) were
measured 1—4 days before and 6—14 days after Nx. Urinary ET-1 excretion
was evaluated by a 12 hour overnight urine collection.
KD before Nx
KD before Nx (calculated
(calculated for one
for two kidneys) kidney) KD after Nx
uET-1 excretion, pg/mm 157.8 54.2 78.9 27.1 170.5 92.41)
pET-i, pg/mI 24,3 2.8 24.3 2.8 24.3 3.1
ET-1 clearance, mI/mm 6.5 2.0 3.3 1.0 7.1 3.8k
GFR, ml/min 86.5 15.5 43.2 7.8 57.8 ll.4'
RPF, mI/mitt 443.1 103.2 221.6 51.6 296.9 64.4a1
fractional ET-1 clearance 0.08 0.02 0.08 0.02 0.13 0.08
Mean SD (N = 10) a PC 0.05 vs. both kidneys before Nx; 1)p < 0.05
vs. one kidney before Nx.
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Mean KD age was 39—72 years (mean SD, 55 10 years). Plasma ET-1,
uET-1 excretion and ET-1 clearance remained unchanged after Nx;
however, ET-1 excretion and clearance per kidney increased two times.
Fractional ET-1 clearance was significantly higher after Nx. Renal adap-
tation after kidney donation includes for one kidney doubling of uET-1
excretion and ET-1 clearance to baseline values before Nx. This increase
apparently seems not to interfere with glomerular hyperfiltration and
hyperperfusion. ET-1 hyperexcretion per kidney may point to an aug-
mented ET-1 production in the tubular department.
Induction of plasminogen activator inhibitor type 1 (PAL-i) in murine
lupus-like glomerulonephritis. S. Moll, PA. Menoud, A.P. Sappino, J.A.
Schifferli, J.D. Vassalli, and S. Izui, Laboratoire de Nephrologie, Laboratoire
d'Onco-Hématologie, Département de Moiphologie, Département de Pa-
thologie, Centre Medical Universitaire, Genève, and Universitatsskliniken,
Basel, Switzerland. Plasminogen activators/plasmin system has been shown
to play a role in the pathogenesis of glomerulonephritis. In the present
study, we analyzed mRNA expression and localization of plasminogen
activators and plasminogen activator inhibitors during development of
glomerular lesions resembling "wire-loop" lupus nephritis induced by
monoclonal IgG3 cryoglobulins. Northern blot analysis revealed a marked
induction in PAT-i mRNA expression (20—40 fold), without any variation
in tPA and uPA mRNA levels. No PAI-2 mRNA was detected in the
course of glomerulonephritis. This enhanced PAT-i expression was exclu-
sively localized in the cortex, with a strong and speckled reinforcement,
suggesting glomerular localization. In parallel, mRNA expression of
transforming growth factor f3 (TGF-I3) was significantly increased (3—4
fold) in the cortex, with the same pattern of distribution as for PAT-i.
Similarly, glomerular up-regulation of both PAT-i and TGF-/3 was ob-
served in lupus-prone BXSB and MRL-lpr mice. These results suggest that
PAT-i up-regulation may participate to the development of murine
lupus-like glomerular lesions, and that TGF-f3 may play an important role
in the induction of PAl-i mRNA expression.
